Pharmacological Potential of <i>Sargassum ilicifolium</i>: Mechanistic Insights into Antidiabetic and Hypolipidemic activity through Chlorogenic Acid-Mediated SGLT2 Inhibition

Background: Diabetes mellitus is a chronic metabolic disorder characterised by hyperglycemia and dyslipidemia, often associated with pancreatic ?-cell damage and altered glucose transport mechanisms. Natural marine products have gained attention as potential sources of safer antidiabetic agents, particularly targeting Sodium Glucose Cotransporter 2 (SGLT2)-mediated glucose reabsorption. Aim: To evaluate the hypolipidemic and antidiabetic activities of Sargassum ilicifolium extract in an alloxan-induced diabetic rat model and to investigate the SGLT2 inhibitory potential of its chief constituent, chlorogenic acid, through in silico and in vitro studies. Methods: Sargassum ilicifolium extract was administered at doses of 200 mg/kg and 400 mg/kg to alloxan-induced diabetic rats. Biochemical parameters, including blood glucose, total cholesterol, Low Density Lipoprotein (LDL), Very Low Density Lipoprotein (VLDL), triglycerides, and High Density Lipoprotein (HDL), were assessed. Histopathological examination of pancreatic tissue was performed to evaluate ?-cell architecture. Chlorogenic acid was isolated and characterised using spectroscopic techniques. Its SGLT2 inhibitory activity was analysed using western blot analysis and 2-NBDG uptake assay in HK-2 cells at IC?? (184 ?g/mL) and IC?? (98 ?g/mL). Results: Treatment with S. ilicifolium extract significantly reduced blood glucose, total cholesterol, LDL, VLDL, and triglyceride levels, and markedly increased HDL levels in diabetic rats. Histological analysis demonstrated restoration of pancreatic ?-cell architecture following treatment. In vitro studies showed a concentration-dependent reduction in SGLT2 protein expression in Human Kidney (HK)-2 cells upon chlorogenic acid treatment. Molecular docking revealed a strong binding affinity of chlorogenic acid with SGLT2 (�8.17 kcal/mol). The 2-NBDG uptake assay showed decreased fluorescence intensity, confirming inhibition of SGLT2-mediated glucose uptake. Conclusion: Sarga

View article page

Download PDF